|Articles|January 2, 2022
- Pharmaceutical Technology, January 2022 Issue
- Volume 46
- Issue 1
Next-Generation Cas9 Proteins
Author(s)Pharmaceutical Technology Editors
Thermo Fisher's Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency.
Thermo Fisher Scientific’s Invitrogen TrueCut Hifi Cas9 Protein is designed for research applications that require highly precise genome editing, such as the engineering of chimeric antigen receptor (CAR)-T cells and the creation of cellular models for disease discovery.
The Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency. It does this by minimizing edits in unintended locations, which are disruptive in translational research, drug screening, and drug modeling. It has demonstrated near complete elimination of off-target effects compared to wild-type Cas9 in several cell types, including T cells and induced pluripotent stem cells (iPSCs), as well as shown improved off-target profiles relative to similar proteins.
Articles in this issue
over 4 years ago
Industrious Pharmaceuticalsover 4 years ago
The Long Path to Normalover 4 years ago
Changes Afoot: 2022 Outlook for Pharma and its Peopleover 4 years ago
Addressing the Training Gap for Single-Use Technologiesover 4 years ago
Taste and Appearance: Selecting the Right Excipientsover 4 years ago
Tackling the Big Issue of Solubilityover 4 years ago
Biologics Testing Highlights Need for Analytical Skillsover 4 years ago
Outsourcing’s Race Toward Noveltyover 4 years ago
Regulating Digital Therapeutics
Trending on Pharmaceutical Technology
1
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
2
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
3
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
4
A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision
5